SciSparc (SPRC) Non Operating Income (2016 - 2022)

SciSparc (SPRC) posted Non Operating Income of -$14.0 million for Q4 2022, down 2731.58% sequentially from -$494000.0 in Q2 2019.

SciSparc (SPRC) Non Operating Income (2016 - 2022) Analysis & Trends

SciSparc has reported Non Operating Income for 5 years, with the latest figure at -$14.0 million in Q4 2022.

Quarterly Non Operating Income changed N/A year-over-year to -$14.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$14.4 million (changed N/A YoY) and the FY2024 annual result came in at -$612000.0, up 72.42% from the prior year.
Non Operating Income retreated to -$14.0 million in Q4 2022 per SPRC's latest filing, from -$494000.0 in the prior quarter.
Over five years, Non Operating Income peaked at $284000.0 in Q1 2019 and troughed at -$14.0 million in Q4 2022.
A 3-year average of -$2.1 million and a median of -$232000.0 in 2018 frame the typical range for Non Operating Income.
The sharpest annual moves came in 2018 and 2019: Non Operating Income slumped 900.0% in 2018, then surged 415.56% in 2019.
Over 3 years, Non Operating Income stood at -$232000.0 in 2018, then tumbled by 112.93% to -$494000.0 in 2019, then slumped by 2731.58% to -$14.0 million in 2022.
According to Business Quant data, Non Operating Income over the past three periods registered -$14.0 million, -$494000.0, and $284000.0 for Q4 2022, Q2 2019, and Q1 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	234.30 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-53.64 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-51.63 Mn
10	SciSparc	831,418.60	831,418.60	-	-

Download Data